Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer

Complete title: A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer

Research Study Number 20170696
Principal Investigator Andrew Coveler, MD
Phase I

Research Study Description

This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20170696
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Gastric Cancer; Pancreatic Cancer; Solid Tumors; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Colorectal Neoplasms; Carcinoma; Endocrine Gland Neoplasms; Immunotherapy; Digestive System Diseases

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials